These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 18571548)

  • 41. Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China.
    Huang H; Jiang J; Shi X; Qin J; Dong J; Xu L; Huang C; Liu Y; Zheng Y; Hou M; Shen Q; Zeng B; Qian G; Yang F; Lv H
    Ann Med; 2022 Dec; 54(1):442-453. PubMed ID: 35099338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.
    Masuda H; Ae R; Koshimizu TA; Kosami K; Makino N; Matsubara Y; Sasahara T; Nakamura Y
    Clin Rheumatol; 2022 Oct; 41(10):3125-3133. PubMed ID: 35798922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
    Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
    Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease.
    Weng KP; Hsieh KS; Ho TY; Huang SH; Lai CR; Chiu YT; Huang SC; Lin CC; Hwang YT; Ger LP
    Circ J; 2010 Mar; 74(3):544-51. PubMed ID: 20081319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Shock and unresponsiveness to repeated courses of intravenous immunoglobulin in Kawasaki disease: a nationwide database study.
    Liang YC; Chang CH; Lin MT; Kao FY; Huang SK; Wu MH
    Pediatr Res; 2020 Apr; 87(5):961-966. PubMed ID: 31711068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
    J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Risk Prediction of Coronary Artery Lesions through the Novel Hematological Z-Values in 4 Chronological Age Subgroups of Kawasaki Disease.
    Cho HJ; Kim WY; Park SM; Lee JH; Shin HJ; Jang GY; Ha KS
    Medicina (Kaunas); 2020 Sep; 56(9):. PubMed ID: 32932823
    [No Abstract]   [Full Text] [Related]  

  • 49. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.
    Rigante D; Valentini P; Rizzo D; Leo A; De Rosa G; Onesimo R; De Nisco A; Angelone DF; Compagnone A; Delogu AB
    Rheumatol Int; 2010 Apr; 30(6):841-6. PubMed ID: 20049445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience.
    Maric LS; Knezovic I; Papic N; Mise B; Roglic S; Markovinovic L; Tesovic G
    Rheumatol Int; 2015 Jun; 35(6):1053-8. PubMed ID: 25429794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study.
    Shao S; Luo C; Zhou K; Hua Y; Wu M; Liu L; Liu X; Wang C
    Pediatr Rheumatol Online J; 2019 Nov; 17(1):78. PubMed ID: 31775782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
    Wang X; Pan SL; DU ZH; Ji ZX; Luo G; Sun HX; Ma SJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):399-404. PubMed ID: 35527415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying Patients With Kawasaki Disease Safe for Early Discharge: Development of a Risk Prediction Model at a US Children's Hospital.
    Hester GZ; Watson D; Nickel AJ; Ryan N; Jepson B; Gray J; Bergmann KR
    Hosp Pediatr; 2019 Oct; 9(10):749-756. PubMed ID: 31501220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
    Kobayashi T; Inoue Y; Takeuchi K; Okada Y; Tamura K; Tomomasa T; Kobayashi T; Morikawa A
    Circulation; 2006 Jun; 113(22):2606-12. PubMed ID: 16735679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of IVIG resistance predictive models in Kawasaki disease.
    Kaya Akca U; Arslanoglu Aydin E; Aykan HH; Serin O; Sag E; Demir S; Atalay E; Kasap M; Batu ED; Karagoz T; Bilginer Y; Ozen S
    Pediatr Res; 2022 Feb; 91(3):621-626. PubMed ID: 33753891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
    Zheng X; Li J; Yue P; Liu L; Li J; Zhou K; Hua Y; Li Y
    PLoS One; 2021; 16(3):e0248812. PubMed ID: 33764989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors in IVIG-resistant Kawasaki disease and correlation with Japanese scoring systems - a study from Eastern India.
    Ahmed N; Pal P; Azad SM; Ghosh A; Banerjee P; Sarkar SD
    Clin Rheumatol; 2023 Jan; 42(1):145-150. PubMed ID: 36053472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients.
    Wang Z; Xu Y; Zhou H; Wang Y; Li W; Lu Z; Jiang Z; Gu X; Zheng H; Zeng L; Huang P; Zhang L; Gu X
    Cardiovasc Ther; 2020; 2020():3568608. PubMed ID: 32256707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.